

World Journal of *Clinical Cases*

World J Clin Cases 2022 August 16; 10(23): 8057-8431



Contents

Thrice Monthly Volume 10 Number 23 August 16, 2022

OPINION REVIEW

- 8057** Invasive intervention timing for infected necrotizing pancreatitis: Late invasive intervention is not late for collection

Xiao NJ, Cui TT, Liu F, Li W

- 8063** Clinical utility of left atrial strain in predicting atrial fibrillation recurrence after catheter ablation: An up-to-date review

Yu ZX, Yang W, Yin WS, Peng KX, Pan YL, Chen WW, Du BB, He YQ, Yang P

MINIREVIEWS

- 8076** Gut microbiota and COVID-19: An intriguing pediatric perspective

Valentino MS, Esposito C, Colosimo S, Caprio AM, Puzone S, Guarino S, Marzuillo P, Miraglia del Giudice E, Di Sessa A

- 8088** Beta receptor blocker therapy for the elderly in the COVID-19 era

Santillo E, Migale M

ORIGINAL ARTICLE

Retrospective Cohort Study

- 8097** Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis

Fallahzadeh MA, Asrani SK, Tapper EB, Saracino G, Rahimi RS

Retrospective Study

- 8107** Different squatting positions after total knee arthroplasty: A retrospective study

Li TJ, Sun JY, Du YQ, Shen JM, Zhang BH, Zhou YG

- 8115** Outcomes of seromuscular bladder augmentation compared with standard bladder augmentation in the treatment of children with neurogenic bladder

Sun XG, Li YX, Ji LF, Xu JL, Chen WX, Wang RY

- 8124** Distinctive clinical features of spontaneous pneumoperitoneum in neonates: A retrospective analysis

Kim SH, Cho YH, Kim HY

- 8133** Cognitive training for elderly patients with early Alzheimer's disease in the Qinghai-Tibet Plateau: A pilot study

Wang XH, Luo MQ

- 8141** Diagnostic value of elevated serum carbohydrate antigen 125 level in sarcoidosis

Zhang Q, Jing XY, Yang XY, Xu ZJ

- 8152** Evaluation of progressive early rehabilitation training mode in intensive care unit patients with mechanical ventilation

Qie XJ, Liu ZH, Guo LM

- 8161** Comparison of demographic features and laboratory parameters between COVID-19 deceased patients and surviving severe and critically ill cases

Wang L, Gao Y, Zhang ZJ, Pan CK, Wang Y, Zhu YC, Qi YP, Xie FJ, Du X, Li NN, Chen PF, Yue CS, Wu JH, Wang XT, Tang YJ, Lai QQ, Kang K

Clinical Trials Study

- 8170** Role of H₂receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial

Mohiuddin Chowdhury ATM, Kamal A, Abbas MKU, Karim MR, Ali MA, Talukder S, Hamidullah Mehedi H, Hassan H, Shahin AH, Li Y, He S

Observational Study

- 8186** Short-term prognostic factors for hepatitis B virus-related acute-on-chronic liver failure

Ye QX, Huang JF, Xu ZJ, Yan YY, Yan Y, Liu LG

- 8196** Three-dimensional psychological guidance combined with evidence-based health intervention in patients with liver abscess treated with ultrasound

Shan YN, Yu Y, Zhao YH, Tang LL, Chen XM

- 8205** Role of serum β 2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy

Yang B, Zhao XH, Ma GB

SYSTEMATIC REVIEWS

- 8212** Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database: A literature review

Cai XC, Wu SD

CASE REPORT

- 8224** Sepsis complicated with secondary hemophagocytic syndrome induced by giant gouty tophi rupture: A case report

Lai B, Pang ZH

- 8232** Spontaneous remission of autoimmune pancreatitis: Four case reports

Zhang BB, Huo JW, Yang ZH, Wang ZC, Jin EH

- 8242** Epstein-Barr-virus-associated hepatitis with aplastic anemia: A case report

Zhang WJ, Wu LQ, Wang J, Lin SY, Wang B

- 8249** Aspiration as the first-choice procedure for airway management in an infant with large epiglottic cysts: A case report

Zheng JQ, Du L, Zhang WY

- 8255** Sequential multidisciplinary minimally invasive therapeutic strategy for heart failure caused by four diseases: A case report
Zhao CZ, Yan Y, Cui Y, Zhu N, Ding XY
- 8262** Primary ascending colon cancer accompanying skip metastases in left shoulder skin and left neck lymph node: A case report
Zhou JC, Wang JJ, Liu T, Tong Q, Fang YJ, Wu ZQ, Hong Q
- 8271** Clinical and genetic study of ataxia with vitamin E deficiency: A case report
Zhang LW, Liu B, Peng DT
- 8277** Complete resection of large-cell neuroendocrine and hepatocellular carcinoma of the liver: A case report
Noh BG, Seo HI, Park YM, Kim S, Hong SB, Lee SJ
- 8284** Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
Xuan TT, Li GY, Meng SB, Wang ZM, Qu LL
- 8291** Bladder malacoplakia: A case report
Wang HK, Hang G, Wang YY, Wen Q, Chen B
- 8298** Delayed inflammatory response evoked in nasal alloplastic implants after COVID-19 vaccination: A case report
Seo MG, Choi EK, Chung KJ
- 8304** Phosphoglyceride crystal deposition disease requiring differential diagnosis from malignant tumors and confirmed by Raman spectroscopy: A case report
Ohkura Y, Uruga H, Shiiba M, Ito S, Shimoyama H, Ishihara M, Ueno M, Udagawa H
- 8312** Vulvovaginal myeloid sarcoma with massive pelvic floor infiltration: A case report and review of literature
Wang JX, Zhang H, Ning G, Bao L
- 8323** Femoral neck stress fracture and medial tibial stress syndrome following high intensity interval training: A case report and review of literature
Tan DS, Cheung FM, Ng D, Cheung TLA
- 8330** Periosteal chondroma of the rib: A case report
Gao Y, Wang JG, Liu H, Gao CP
- 8336** Papillary thyroid carcinoma occurring with undifferentiated pleomorphic sarcoma: A case report
Lee YL, Cheng YQ, Zhu CF, Huo HZ
- 8344** Laparoscopic treatment of bilateral duplex kidney and ectopic ureter: A case report
Wang SB, Wan L, Wang Y, Yi ZJ, Xiao C, Cao JZ, Liu XY, Tang RP, Luo Y
- 8352** Incontinentia pigmenti with intracranial arachnoid cyst: A case report
Li WC, Li ML, Ding JW, Wang L, Wang SR, Wang YY, Xiao LF, Sun T

- 8360** Relapsing polychondritis causing breathlessness: Two case reports
Zhai SY, Zhang YH, Guo RY, Hao JW, Wen SX
- 8367** Endodontic management of a fused left maxillary second molar and two paramolars using cone beam computed tomography: A case report
Mei XH, Liu J, Wang W, Zhang QX, Hong T, Bai SZ, Cheng XG, Tian Y, Jiang WK
- 8375** Infant biliary cirrhosis secondary to a biliary inflammatory myofibroblastic tumor: A case report and review of literature
Huang Y, Shu SN, Zhou H, Liu LL, Fang F
- 8384** Metastatic low-grade endometrial stromal sarcoma with variable morphologies in the ovaries and mesentery: A case report
Yu HY, Jin YL
- 8392** Bronchogenic cysts with infection in the chest wall skin of a 64-year-old asymptomatic patient: A case report
Ma B, Fu KW, Xie XD, Cheng Y, Wang SQ
- 8400** Incidental accumulation of Technetium-99m pertechnetate in subacute cerebral infarction: A case report
Han YH, Jeong HJ, Kang HG, Lim ST
- 8406** Metal stent combined with ileus drainage tube for the treatment of delayed rectal perforation: A case report
Cheng SL, Xie L, Wu HW, Zhang XF, Lou LL, Shen HZ
- 8417** Using ketamine in a patient with a near-occlusion tracheal tumor undergoing tracheal resection and reconstruction: A case report
Xu XH, Gao H, Chen XM, Ma HB, Huang YG

LETTER TO THE EDITOR

- 8422** Reflections on the prevalence of human leukocyte antigen-B27 and human leukocyte antigen-B51 co-occurrence in patients with spondylarthritis
Gonçalves Júnior J, Sampaio-Barros PD, Shinjo SK
- 8425** Comment on "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy"
Argyriou K, Kotsakis A
- 8428** Intranasal sufentanil combined with intranasal dexmedetomidine: A promising method for non-anesthesiologist sedation during endoscopic ultrasonography
Wang Y, Ge ZJ, Han C

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Peng Liang, MD, Associate Professor, Day Surgery Center, Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China. 39485572@qq.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

August 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Retrospective Study

Comparison of demographic features and laboratory parameters between COVID-19 deceased patients and surviving severe and critically ill cases

Lei Wang, Yang Gao, Zhao-Jin Zhang, Chang-Kun Pan, Ying Wang, Yu-Cheng Zhu, Yan-Peng Qi, Feng-Jie Xie, Xue Du, Na-Na Li, Peng-Fei Chen, Chuang-Shi Yue, Ji-Han Wu, Xin-Tong Wang, Yu-Jia Tang, Qi-Qi Lai, Kai Kang

Specialty type: Critical care medicine

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Aguiar P, Spain; Vaquero L, Spain

Received: April 6, 2022

Peer-review started: April 6, 2022

First decision: May 11, 2022

Revised: May 15, 2022

Accepted: July 11, 2022

Article in press: July 11, 2022

Published online: August 16, 2022



Lei Wang, Xue Du, Na-Na Li, Peng-Fei Chen, Chuang-Shi Yue, Ji-Han Wu, Xin-Tong Wang, Yu-Jia Tang, Qi-Qi Lai, Kai Kang, Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China

Yang Gao, Department of Critical Care Medicine, The Sixth Affiliated Hospital of Harbin Medical University, Harbin 150028, Heilongjiang Province, China

Zhao-Jin Zhang, Department of Critical Care Medicine, The Yichun Forestry Administration Central Hospital, Yichun 153000, Heilongjiang Province, China

Chang-Kun Pan, Department of Critical Care Medicine, The Jiamusi Cancer Hospital, Jiamusi 154007, Heilongjiang Province, China

Ying Wang, Department of Critical Care Medicine, The First People Hospital of Mudanjiang City, Mudanjiang 157011, Heilongjiang Province, China

Yu-Cheng Zhu, Department of Critical Care Medicine, The Hongxinglong Hospital of Beidahuang Group, Shuangyashan 155811, Heilongjiang Province, China

Yan-Peng Qi, Department of Cardiology, The Hongxinglong Hospital of Beidahuang Group, Shuangyashan 155811, Heilongjiang Province, China

Feng-Jie Xie, Department of Critical Care Medicine, The Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang 157011, Heilongjiang Province, China

Corresponding author: Kai Kang, MMed, Chief Doctor, Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, No. 23 Post Street, Harbin 150001, Heilongjiang Province, China. janeck79@126.com

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) has been far more devastating than expected, showing no signs of slowing down at present. Heilongjiang Province is the most northeastern province of China, and has cold weather for nearly half a

year and an annual temperature difference of more than 60°C, which increases the underlying morbidity associated with pulmonary diseases, and thus leads to lung dysfunction. The demographic features and laboratory parameters of COVID-19 deceased patients in Heilongjiang Province, China with such climatic characteristics are still not clearly illustrated.

AIM

To illustrate the demographic features and laboratory parameters of COVID-19 deceased patients in Heilongjiang Province by comparing with those of surviving severe and critically ill cases.

METHODS

COVID-19 deceased patients from different hospitals in Heilongjiang Province were included in this retrospective study and compared their characteristics with those of surviving severe and critically ill cases in the COVID-19 treatment center of the First Affiliated Hospital of Harbin Medical University. The surviving patients were divided into severe group and critically ill group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (the seventh edition). Demographic data were collected and recorded upon admission. Laboratory parameters were obtained from the medical records, and then compared among the groups.

RESULTS

Twelve COVID-19 deceased patients, 27 severe cases and 26 critically ill cases were enrolled in this retrospective study. No differences in age, gender, and number of comorbidities between groups were found. Neutrophil percentage (NEUT%), platelet (PLT), C-reactive protein (CRP), creatine kinase isoenzyme (CK-MB), serum troponin I (TNI) and brain natriuretic peptides (BNP) showed significant differences among the groups ($P = 0.020$, $P = 0.001$, $P < 0.001$, $P = 0.001$, $P < 0.001$, $P < 0.001$, respectively). The increase of CRP, D-dimer and NEUT% levels, as well as the decrease of lymphocyte count (LYMPH) and PLT counts, showed significant correlation with death of COVID-19 patients ($P = 0.023$, $P = 0.008$, $P = 0.045$, $P = 0.020$, $P = 0.015$, respectively).

CONCLUSION

Compared with surviving severe and critically ill cases, no special demographic features of COVID-19 deceased patients were observed, while some laboratory parameters including NEUT%, PLT, CRP, CK-MB, TNI and BNP showed significant differences. COVID-19 deceased patients had higher CRP, D-dimer and NEUT% levels and lower LYMPH and PLT counts.

Key Words: COVID-19; SARS-CoV-2; Deceased patients; C-reactive protein; D-dimer; Neutrophil percentage; Lymphocyte count; Platelet

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Early detection and intervention of coronavirus disease 2019 (COVID-19) patients with a higher risk of death will contribute to rationally allocate limited medical resources and reduce the case-fatality rate. Our results illustrated that some laboratory parameters, including neutrophil percentage (NEUT%), platelet (PLT), C-reactive protein (CRP), creatine kinase isoenzyme, serum troponin I and brain natriuretic peptides showed significant differences in COVID-19 deceased patients compared with surviving severe and critically ill cases. COVID-19 deceased patients had higher CRP, D-dimer and NEUT% levels and lower lymphocyte count and PLT counts. Our study added evidence to the notion that the pathogenesis of COVID-19 deceased patients was related to the superimposed bacterial or fungal infection, cellular immune deficiency, coagulation disorder, activation of inflammatory cytokine responses, and impaired organ function, which in turn could interact with each other, forming a complicated network.

Citation: Wang L, Gao Y, Zhang ZJ, Pan CK, Wang Y, Zhu YC, Qi YP, Xie FJ, Du X, Li NN, Chen PF, Yue CS, Wu JH, Wang XT, Tang YJ, Lai QQ, Kang K. Comparison of demographic features and laboratory parameters between COVID-19 deceased patients and surviving severe and critically ill cases. *World J Clin Cases* 2022; 10(23): 8161-8169

URL: <https://www.wjgnet.com/2307-8960/full/v10/i23/8161.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i23.8161>

INTRODUCTION

Coronavirus disease 2019 (COVID-19) has been far more devastating than expected, showing no signs of slowing down at present. COVID-19 has led to more deaths than the sum of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome CoV infection. The case-fatality rate of COVID-19 as reported previously varied from 3.77% to 28% in Wuhan (epicenter area)[1-8], and this percentage was significantly higher than that in other non-epicenter areas of China[7,9]. The two consecutive outbreaks of the epidemic resulted in a total of 559 locally confirmed cases and 13 deceased patients in the Heilongjiang Province, China, with a crude case-fatality rate of about 2.3%, which is lower than the national average of 5.58% (4634/83027). This once again suggested that continuously enriching the management of COVID-19 and gradually alleviating the temporary shortage of public health capacity could effectively reduce the case-fatality rate[9], although its reasons might be manifold[7]. Studies on COVID-19 deceased patients were of great significance as they contribute to better understand the underlying pathogenesis of it, especially in other regions of China with different demographic characteristics, except Hubei Province.

Angiotensin converting enzyme 2 (ACE2) is the functional host receptor for SARS-CoV-2 and route of viral entry. It is mainly distributed in the alveolar epithelial type II cells[10,11], and so a high prevalence of pneumonia is observed in COVID-19 patients clinically rather than upper respiratory symptoms. ACE2 had stronger binding affinity with SARS-CoV-2 than SARS-CoV, and this might account for its greater pathogenicity[12]. Heilongjiang Province is the most northeastern province of China, and has cold weather for nearly half a year and an annual temperature difference of more than 60°C, which increases the underlying morbidity associated with pulmonary diseases, and thus leads to lung dysfunction[13,14]. Chronic pulmonary disease plays an important role in predicting the in-hospital mortality in critically ill patients and even contributes to the case-fatality rate of COVID-19 patients[15, 16]. What are the demographic features and laboratory parameters of COVID-19 deceased patients in Heilongjiang Province with such climatic characteristics remains a question.

To better address the above issue, the demographic features and laboratory parameters of COVID-19 deceased patients in Heilongjiang Province were compared with those of surviving severe and critically ill cases. This study was conducted in order to better understand the underlying pathogenesis of COVID-19 deceased patients, identify these patients as early as possible, guide clinical treatment regimens, and thus improve the clinical outcomes.

MATERIALS AND METHODS

Study design

The COVID-19 deceased patients from different hospitals in Heilongjiang Province, China were included in this retrospective study and compared with the severe and critically ill cases who survived from the COVID-19 treatment center of the First Affiliated Hospital of Harbin Medical University. The surviving patients were identified as severe group and critically ill group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (the seventh edition). Demographic data were collected and recorded upon admission. Laboratory parameters, including white blood cell count (WBC), neutrophil percentage (NEUT%), lymphocyte count (LYMPH), platelet (PLT) count, fibrinogen (FIB), D-Dimer, C-reaction protein (CRP), albumin (ALB), creatinine (CRE), creatine kinase isoenzyme (CK-MB), serum troponin I (TNI) and brain natriuretic peptides (BNP) levels were obtained from the medical records, and then were compared among the groups. This study was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University (IRB number: IRB-AF/SC-04).

Study population

Twelve COVID-19 deceased patients, 27 severe cases and 26 critically ill cases were enrolled in this retrospective study. The respiratory samples of all enrolled COVID-19 patients were confirmed by SARS-CoV-2 nucleic acid detection. COVID-19 patients with incomplete medical records were excluded from the study.

Data collection

Demographic data, including age, gender and number of comorbidities, and laboratory parameters, including WBC, NEUT%, LYMPH, PLT, FIB, D-dimer, CRP, ALB, CRE, CK-MB, TNI and BNP were collected and recorded from the medical records through dedicated personnel. The members of our research group were unaware of the patient's private information other than the data acquired for this study.

Statistical analysis

SPSS 22.0 (SPSS Inc., Chicago, IL, United States) was adopted for statistical analyses. Analysis of variance (ANOVA), χ^2 test and Kruskal-Wallis rank sum test were employed for performing intergroup

comparison of age, gender and number of comorbidities. Kruskal-Wallis rank sum test was used for intergroup comparison of CRP due to non-normal distribution, while one-way ANOVA was employed for intergroup comparison of other laboratory parameters with normal distribution. Pair-wise comparison was completed by least significance difference. Pearson correlation analysis was used to analyze the correlation between dynamic profile of laboratory parameters and death of COVID-19 patients. *P* values of < 0.05 were considered as statistically significant.

RESULTS

Intergroup comparison of age, gender, and number of comorbidities

The ratio of COVID-19 deceased patients in men and women was 1:1, with a median age of 71.50 years. A quarter of these deceased patients demonstrated no comorbidities. COVID-19 deceased patients with 1, 2, 3, and 4 types of comorbidities accounted for 25.0%, 25.0%, 8.3% and 16.7% respectively. As shown in Table 1, there were no differences in age, gender, and number of comorbidities among the groups.

Intergroup comparison of laboratory parameters

As shown in Table 2, laboratory parameters, including NEUT%, PLT, CRP, CK-MB, TNI and BNP showed significant differences among the groups ($P = 0.020$, $P = 0.001$, $P < 0.001$, $P = 0.001$, $P < 0.001$, $P < 0.001$, respectively), except for WBC, LYMPH, FIB, D-dimer, ALB and CRE ($P = 0.131$, $P = 0.220$, $P = 0.809$, $P = 0.766$, $P = 0.306$, $P = 0.923$, respectively).

The correlation between dynamic profile of laboratory parameters and death of COVID-19 patients

The increase in CRP, D-dimer and NEUT% levels, as well as the decrease of LYMPH and PLT counts showed significant correlation with the death of COVID-19 patients ($P = 0.023$, $P = 0.008$, $P = 0.045$, $P = 0.020$, $P = 0.015$, respectively) (Table 3).

DISCUSSION

As a highly pathogenic human CoV, SARS-CoV-2 had unprecedented pathogenicity and complex clinical manifestations that range from asymptomatic infection to fatal pneumonia. In China, about 15%-30% confirmed COVID-19 patients developed into severe and critically ill cases, usually presenting with acute respiratory distress syndrome and requiring some form of ventilatory support[1,2,17,18]. The case-fatality rate of critically ill patients with COVID-19 even exceeded 60%[19]. At present, the number of COVID-19 deceased patients worldwide has exceeded six million without any sign of slowing down. Moreover, the absence of available specific medications for treating COVID-19 was a clinical reality. Therefore, there is an urgent need to understand the demographic features and laboratory parameters of COVID-19 deceased patients in clinical practice so as to identify and intervene in the early stage and thus improve the clinical outcomes, and explore the underlying pathogenesis by comparing with those of surviving severe and critically ill cases.

At present, most of the studies on COVID-19 deceased patients in China were concentrated in Wuhan but lacked in other regions. Different generations of SARS-CoV-2 infection in patients with different demographic characteristics have inevitably led to different clinical characteristics[20]. Heilongjiang Province has unique climatic characteristics that affect lung function and the morbidity associated with respiratory diseases. The two consecutive outbreaks of COVID-19 in Heilongjiang Province were related to secondary or tertiary transmission of imported cases from Wuhan and the United States[21]. The question is that whether COVID-19 deceased patients caused by secondary or tertiary transmission of imported cases in Heilongjiang Province have special demographic features and laboratory parameters?

In our study, COVID-19 deceased patients in Heilongjiang Province included men and women in 1:1 ratio with a median age of 71.50 years. Contrary to the results of other studies, no differences were observed in age, gender, and number of comorbidities in COVID-19 deceased patients when compared to surviving severe and critically ill cases. The primary reason for this is that only COVID-19 deceased patients, and surviving severe and critically ill cases were collected in our study, lacking asymptomatic, mild, and moderate cases. We believed that comparing asymptomatic, mild, and moderate cases with COVID-19 deceased patients would expand the clinical characteristics that were associated with poor outcomes and confuse the true facts. COVID-19 patients included in our study were significantly older than those reported in other studies[3,22-24], and this might be a reason partly.

It has been widely accepted that SARS-CoV-2 infection causes a decrease in the absolute number of lymphocyte count, especially in severe and critically ill cases, and deceased patients[1,6,16,24,25]. The inhibited and delayed interferon (IFN) response signaling induced by SARS-CoV infection sensitized T cells to apoptosis *via* tumor necrosis factor-mediated pathway[26]. Furthermore, IFN weakens the T cell responses by up-regulating the expression of negative immune regulatory molecules[27]. It is speculated that due to high degree of homology, the mechanism on destruction of lymphocytes by

Table 1 Intergroup comparison of age, gender, and number of comorbidities

	COVID-19 deceased patients	Critically ill group	Severe group	<i>F</i> / χ^2	<i>P</i> value
Age	71.50 ± 10.41	63.78 ± 11.58	65.59 ± 11.75	1.978	0.147
Gender				0.053	0.974
Female	6	12	13		
Male	6	14	14		
Number of comorbidities				4.251	0.119
0	3	12	8		
1	3	9	6		
2	3	2	8		
3	1	2	5		
4	2	1	0		

COVID-19: Coronavirus disease 2019.

Table 2 Intergroup comparison of laboratory parameters

Laboratory parameters	COVID-19 deceased patients	Critically ill group	Severe group	<i>F</i> / χ^2	<i>P</i> value
WBC	7.65 ± 6.62	7.58 ± 2.32	5.77 ± 2.32	2.103	0.131
NEUT%	75.35 ± 11.41	82.19 ± 10.25	72.62 ± 14.13 ¹	4.151	0.020
LYMPH	1.08 ± 0.98	0.72 ± 0.48	0.89 ± 0.48	1.554	0.220
PLT	141.62 ± 59.88	261.69 ± 110.42 ¹	238.04 ± 119.17 ¹	5.301	0.001
FIB	4.28 ± 2.01	4.68 ± 2.23	4.78 ± 1.96	0.212	0.809
D-Dimer	3.22 ± 5.98	6.43 ± 8.18	6.25 ± 16.49	0.268	0.766
CRP	107.20(147.11)	31.15(44.10) ¹	24.37(32.65) ¹	15.846	< 0.001
ALB	31.10 ± 4.49	29.07 ± 3.95	30.44 ± 3.99	1.208	0.306
CRE	61.44 ± 23.04	63.26 ± 47.38	66.26 ± 28.08	0.081	0.923
CK-MB	45.74 ± 67.48	7.77 ± 8.65 ¹	8.07 ± 6.44 ¹	7.941	0.001
TNI	1.32 ± 1.97	0.03 ± 0.03 ¹	0.01 ± 0.01 ¹	13.504	< 0.001
BNP	575.50 ± 484.94	164.80 ± 225.64 ¹	63.04 ± 66.25 ¹	10.614	< 0.001

¹Represent significant differences compared with coronavirus disease 2019 deceased patients.

COVID-19: Coronavirus disease 2019; WBC: White blood cell count; NEUT%: Neutrophil percentage; LYMPH: Lymphocyte count; PLT: Platelet; FIB: Fibrinogen; CRP: C-reaction protein; ALB: Albumin; CRE: Creatinine; CK-MB: Creatine kinase isoenzyme; TNI: Serum troponin I; BNP: Brain natriuretic peptides.

SARS-CoV-2, as a similarly enveloped RNA virus, is known to be involved, but further studies are needed to confirm these. Therefore, a dynamic decrease in lymphocyte count is considered as an important sign of cellular immune deficiency and an indicator for disease progression[28]. As a prototypical acute phase serum protein, CRP is rapidly elevated in excessive host inflammatory response to virus invasion, becoming a useful marker for the severity of inflammatory response[29]. Complications from hypercoagulability induced by COVID-19 have been reported recently[30,31]. Due to wide distribution of ACE2 receptors in multiple organs[11], SARS-CoV-2 infection could cause multiple organ dysfunction[19,24,28,32], including heart damage in our results.

The abnormalities in the levels of NEUT%, LYMPH, D-dimer, PLT, CRP, CK-MB, TNI and BNP usually indicated superimposed bacterial or fungal infection, cellular immune deficiency, coagulation disorder, activation of inflammatory cytokine responses, and impaired cardiac function. Close monitoring of the dynamic profile of the above laboratory parameters is considered essential for identifying COVID-19 patients who are at risk of poor outcomes in time. Our study added evidence to

Table 3 The correlation between dynamic profile of laboratory parameters and death of coronavirus disease 2019 patients

	CK-MB	CRE	CRP	D-dimer	FIB	LYMPH	NEUT%	PLT	TNI	WBC
Correlation coefficient	-0.122	0.364	0.675 ¹	0.746 ¹	-0.533	-0.684 ¹	0.613 ¹	-0.709 ¹	0.464	0.238
Significance	0.721	0.271	0.023	0.008	0.091	0.020	0.045	0.015	0.177	0.481

¹Significant correlation with the death of coronavirus disease 2019 patients.

CK-MB: Creatine kinase isoenzyme; CRE: Creatinine; CRP: C-reactive protein; FIB: Fibrinogen; LYMPH: Lymphocyte count; NEUT%: Neutrophil percentage; PLT: Platelet; TNI: Serum troponin I; WBC: White blood cell count.

the notion that the pathogenesis of COVID-19 deceased patients was related to the superimposed bacterial or fungal infection, cellular immune deficiency, coagulation disorder, activation of inflammatory cytokine responses, and impaired organ function[33], which in turn could interact with each other, forming a complicated network.

However, there are several limitations in our study. Firstly, retrospective study with small sample size decreases the credibility of our conclusion, and should be further verified in larger sample size in the near future. Secondly, interventions to COVID-19 deceased patients from different hospitals in Heilongjiang Province are uneven, which might have impact on the results of our study. Thirdly, no further analysis of specific comorbidities was performed because of small sample size. Finally, the observational indicators included in our study are limited to demographic features and laboratory parameters, and lacked more comprehensive and in-depth indexes that reveal the pathogenesis of COVID-19 deceased patients.

CONCLUSION

In summary, the crude case-fatality rate of COVID-19 in Heilongjiang Province, which is the most northeastern province in China, was 2.3%. Our study added evidence to the notion that the pathogenesis of COVID-19 deceased patients was related to the superimposed bacterial or fungal infection, cellular immune deficiency, coagulation disorder, activation of inflammatory cytokine responses, and impaired organ function, which in turn could interact with each other, forming a complicated network. Further clinical or animal trials should focus on identification of specific pathogenesis after SARS-CoV-2 invasion.

ARTICLE HIGHLIGHTS

Research background

The coronavirus disease 2019 (COVID-19) has been far more devastating than expected, however, the demographic features and laboratory parameters of COVID-19 deceased patients in Heilongjiang Province, China are still not clearly illustrated.

Research motivation

This study was conducted in order to better understand the underlying pathogenesis of COVID-19 deceased patients, identify these patients as early as possible, guide clinical treatment regimens, and thus improve the clinical outcomes.

Research objectives

In this study, we aimed to illustrate the demographic features and laboratory parameters of COVID-19 deceased patients in Heilongjiang Province by comparing with those of surviving severe and critically ill cases.

Research methods

COVID-19 deceased patients from different hospitals in Heilongjiang Province were included in this retrospective study and compared their characteristics with those of surviving severe and critically ill cases in the COVID-19 treatment center of the First Affiliated Hospital of Harbin Medical University. The surviving patients were divided into severe group and critically ill group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (the seventh edition). Demographic data were collected and recorded upon admission. Laboratory parameters were obtained from the medical records, and then compared among the groups.

Research results

Twelve COVID-19 deceased patients, 27 severe cases and 26 critically ill cases were enrolled in this retrospective study. No differences in age, gender, and number of comorbidities between groups were found. Some laboratory parameters showed significant differences among the groups. The increase of C-reactive protein (CRP), D-dimer and neutrophil percentage (NEUT%) levels, as well as the decrease of lymphocyte count (LYMPH) and platelet (PLT) counts, showed significant correlation with death of COVID-19 patients.

Research conclusions

Compared with surviving severe and critically ill cases, no special demographic features of COVID-19 deceased patients were observed, while some laboratory parameters showed significant differences. COVID-19 deceased patients had higher CRP, D-dimer and NEUT% levels and lower LYMPH and PLT counts.

Research perspectives

COVID-19 deceased patients had higher CRP, D-dimer and NEUT% levels and lower LYMPH and PLT counts.

ACKNOWLEDGEMENTS

We are grateful to all colleagues who worked with us in the COVID-19 treatment center of Heilongjiang Province, and all those who provided selfless advice and help for this article. We pay tribute to the medical staff who lost their lives in the national fight against the COVID-19 epidemic.

FOOTNOTES

Author contributions: Wang L, Gao Y, and Kang K took part in the conception, literature search, study design, statistical analysis, analysis and discussion of results, and manuscript preparation, editing, and review; Zhang ZJ, Pan CK, Wang Y, Zhu YC, Qi YP, Xie FJ, Du X, Li NN, Chen PF, Yue CS, Wu JH, Wang XT, Tang YJ, and Lai QQ provided assistance for the conception, literature search, data acquisition and collation, statistical analysis, analysis and discussion of results, and manuscript preparation; Wang L and Gao Y contributed equally to this work; all authors read and approve the final manuscript.

Supported by National Natural Science Foundation of China, No. 81902000.

Institutional review board statement: This study was approved by the Ethics Committee of The First Affiliated Hospital of Harbin Medical University.

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Lei Wang 0000-0001-8464-6703; Yang Gao 0000-0002-0612-0818; Zhao-Jin Zhang 0000-0002-0655-3197; Chang-Kun Pan 0000-0001-9878-4461; Ying Wang 0000-0002-1716-5974; Yu-Cheng Zhu 0000-0002-0447-9894; Yan-Peng Qi 0000-0003-2987-242X; Feng-Jie Xie 0000-0001-6229-7039; Xue Du 0000-0003-3563-7389; Na-Na Li 0000-0002-0683-3439; Peng-Fei Chen 0000-0003-1963-1171; Chuang-Shi Yue 0000-0002-3688-3357; Ji-Han Wu 0000-0003-1332-0639; Xin-Tong Wang 0000-0001-7895-0178; Yu-Jia Tang 0000-0003-4113-0779; Qi-Qi Lai 0000-0003-0411-5158; Kai Kang 0000-0001-9694-4505.

S-Editor: Wang JL

L-Editor: A

P-Editor: Wang JL

REFERENCES

- 1 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: [31986264](#) DOI: [10.1016/S0140-6736\(20\)30183-5](#)]
- 2 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: [32007143](#) DOI: [10.1016/S0140-6736\(20\)30211-7](#)]
- 3 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: [32171076](#) DOI: [10.1016/S0140-6736\(20\)30566-3](#)]
- 4 **Zhang J**, Wang X, Jia X, Li J, Hu K, Chen G, Wei J, Gong Z, Zhou C, Yu H, Yu M, Lei H, Cheng F, Zhang B, Xu Y, Wang G, Dong W. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect* 2020; **26**: 767-772 [PMID: [32304745](#) DOI: [10.1016/j.cmi.2020.04.012](#)]
- 5 **Wang K**, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, Zhang H, Chen X, Liu C. Clinical and Laboratory Predictors of In-hospital Mortality in Patients With Coronavirus Disease-2019: A Cohort Study in Wuhan, China. *Clin Infect Dis* 2020; **71**: 2079-2088 [PMID: [32361723](#) DOI: [10.1093/cid/ciaa538](#)]
- 6 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: [32031570](#) DOI: [10.1001/jama.2020.1585](#)]
- 7 **Liang WH**, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, Liu XQ, Sang L, Chen RC, Tang CL, Wang T, Wang W, He QH, Chen ZS, Wong SS, Zanin M, Liu J, Xu X, Huang J, Li JF, Ou LM, Cheng B, Xiong S, Xie ZH, Ni ZY, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. *Eur Respir J* 2020; **55** [PMID: [32269086](#) DOI: [10.1183/13993003.00562-2020](#)]
- 8 **Cao J**, Hu X, Cheng W, Yu L, Tu WJ, Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. *Intensive Care Med* 2020; **46**: 851-853 [PMID: [32123993](#) DOI: [10.1007/s00134-020-05987-7](#)]
- 9 **Sun Q**, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. *Ann Intensive Care* 2020; **10**: 33 [PMID: [32189136](#) DOI: [10.1186/s13613-020-00650-2](#)]
- 10 **Zhang H**, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med* 2020; **46**: 586-590 [PMID: [32125455](#) DOI: [10.1007/s00134-020-05985-9](#)]
- 11 **Zhou P**, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**: 270-273 [PMID: [32015507](#) DOI: [10.1038/s41586-020-2012-7](#)]
- 12 **Gheblawi M**, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ Res* 2020; **126**: 1456-1474 [PMID: [32264791](#) DOI: [10.1161/CIRCRESAHA.120.317015](#)]
- 13 **Lin Z**, Gu Y, Liu C, Song Y, Bai C, Chen R, Chen S, Kan H. Effects of ambient temperature on lung function in patients with chronic obstructive pulmonary disease: A time-series panel study. *Sci Total Environ* 2018; **619-620**: 360-365 [PMID: [29156256](#) DOI: [10.1016/j.scitotenv.2017.11.035](#)]
- 14 **Hansel NN**, McCormack MC, Kim V. The Effects of Air Pollution and Temperature on COPD. *COPD* 2016; **13**: 372-379 [PMID: [26683097](#) DOI: [10.3109/15412555.2015.1089846](#)]
- 15 **Shi Q**, Zhang X, Jiang F, Hu N, Bimu C, Feng J, Yan S, Guan Y, Xu D, He G, Chen C, Xiong X, Liu L, Li H, Tao J, Peng Z, Wang W. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. *Diabetes Care* 2020; **43**: 1382-1391 [PMID: [32409504](#) DOI: [10.2337/dc20-0598](#)]
- 16 **Sun H**, Ning R, Tao Y, Yu C, Deng X, Zhao C, Meng S, Tang F, Xu D. Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study. *J Am Geriatr Soc* 2020; **68**: E19-E23 [PMID: [32383809](#) DOI: [10.1111/jgs.16533](#)]
- 17 **Qiu H**, Tong Z, Ma P, Hu M, Peng Z, Wu W, Du B; China Critical Care Clinical Trials Group (CCCCTG). Intensive care during the coronavirus epidemic. *Intensive Care Med* 2020; **46**: 576-578 [PMID: [32077996](#) DOI: [10.1007/s00134-020-05966-y](#)]
- 18 **Wu Z**, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; **323**: 1239-1242 [PMID: [32091533](#) DOI: [10.1001/jama.2020.2648](#)]
- 19 **Yang X**, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**: 475-481 [PMID: [32105632](#) DOI: [10.1016/S2213-2600\(20\)30079-5](#)]
- 20 **Xu XW**, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020; **368**: m606 [PMID: [32075786](#) DOI: [10.1136/bmj.m606](#)]
- 21 **Chen Q**, Gao Y, Wang CS, Kang K, Yu H, Zhao MY, Yu KJ. Exploration of transmission chain and prevention of the

- recurrence of coronavirus disease 2019 in Heilongjiang Province due to in-hospital transmission. *World J Clin Cases* 2021; **9**: 5420-5426 [PMID: [34307595](#) DOI: [10.12998/wjcc.v9.i20.5420](#)]
- 22 **Wu C**, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; **180**: 934-943 [PMID: [32167524](#) DOI: [10.1001/jamainternmed.2020.0994](#)]
 - 23 **Giacomelli A**, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, Bonazzetti C, Covizzi A, Schiuma M, Passerini M, Piscaglia M, Coen M, Gubertini G, Rizzardini G, Cogliati C, Brambilla AM, Colombo R, Castelli A, Rech R, Riva A, Torre A, Meroni L, Rusconi S, Antinori S, Galli M. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacol Res* 2020; **158**: 104931 [PMID: [32446978](#) DOI: [10.1016/j.phrs.2020.104931](#)]
 - 24 **Deng Y**, Liu W, Liu K, Fang YY, Shang J, Zhou L, Wang K, Leng F, Wei S, Chen L, Liu HG. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. *Chin Med J (Engl)* 2020; **133**: 1261-1267 [PMID: [32209890](#) DOI: [10.1097/CM9.0000000000000824](#)]
 - 25 **Sun Y**, Dong Y, Wang L, Xie H, Li B, Chang C, Wang FS. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. *J Autoimmun* 2020; **112**: 102473 [PMID: [32439209](#) DOI: [10.1016/j.jaut.2020.102473](#)]
 - 26 **Channappanavar R**, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe* 2016; **19**: 181-193 [PMID: [26867177](#) DOI: [10.1016/j.chom.2016.01.007](#)]
 - 27 **Teijaro JR**, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. Persistent LCMV infection is controlled by blockade of type I interferon signaling. *Science* 2013; **340**: 207-211 [PMID: [23580529](#) DOI: [10.1126/science.1235214](#)]
 - 28 **Li X**, Wang L, Yan S, Yang F, Xiang L, Zhu J, Shen B, Gong Z. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. *Int J Infect Dis* 2020; **94**: 128-132 [PMID: [32251805](#) DOI: [10.1016/j.ijid.2020.03.053](#)]
 - 29 **Marnell L**, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. *Clin Immunol* 2005; **117**: 104-111 [PMID: [16214080](#) DOI: [10.1016/j.clim.2005.08.004](#)]
 - 30 **Danai GB**, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? *Eur Heart J* 2020; **41**: 1858 [PMID: [32227120](#) DOI: [10.1093/eurheartj/ehaa254](#)]
 - 31 **Magro C**, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res* 2020; **220**: 1-13 [PMID: [32299776](#) DOI: [10.1016/j.trsl.2020.04.007](#)]
 - 32 **Yang F**, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. *J Med Virol* 2020; **92**: 2511-2515 [PMID: [32293741](#) DOI: [10.1002/jmv.25891](#)]
 - 33 **Gao Y**, Wang C, Kang K, Peng Y, Luo Y, Liu H, Yang W, Zhao M, Yu K. Cytokine Storm May Not Be the Chief Culprit for the Deterioration of COVID-19. *Viral Immunol* 2021; **34**: 336-341 [PMID: [33202195](#) DOI: [10.1089/vim.2020.0243](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

